Global Anticoagulant Reversal Drugs Market - Snapshot

Anticoagulant reversal drugs are required to reverse the effect of anticoagulation in certain situations such as unplanned surgery, overdose of anticoagulant therapy, and uncontrolled bleeding.

The global anticoagulant reversal drugs market is anticipated to expand at a high CAGR during the forecast period. Growth of the market can be attributed to rise in prevalence of atrial fibrillation, increase in prevalence of intracranial hemorrhages and gastrointestinal hemorrhages, new technology add-on status (NTAP) offered to certain specific drugs, focus on the development of specific drugs for the reversal of the action of anticoagulants, strong pipeline of drugs, unmet clinical needs due to lack of specific drugs for anticoagulant reversal, and significant opportunities in the emerging markets. However, the risk associated with the reversal of anticoagulation and challenges in the development of anticoagulant reversal drugs including stringent clinical trial regulations are expected to hamper the growth of the global market.

anticoagulant reversal drugs market

In terms of product, the global anticoagulant reversal drugs market has been segmented into prothrombin complex concentrates, vitamin K, protamine, tranexamic acid, idarucizumab, AndeXXa, and others. AndeXXa is considered to be a blockbuster drug. Approval of the drug by the U.S. FDA in 2018 and mode of action to reverse factor Xa inhibitors boost the growth of the segment. Moreover, it is the only available approved drug for the reversal of factor Xa inhibitors. Significant rise in the number of hospital admissions due to factor Xa inhibitors and high cost of AndeXXa (wholesale price is around US$ 27,500) are projected to drive the AndeXXa segment during the forecast period. Furthermore, AndeXXa has significant potential to address factor Xa inhibitors bleeding, which is one of the major causes of hospital admissions and death in developed countries. Favorable reimbursement for this drug and new-technology add-on payment (NTAP) offered contributed to the growth of the segment.

In terms of distribution channel, the global anticoagulant reversal drugs market has been classified into hospital pharmacies, retail pharmacies, and others. The hospital pharmacies segment dominated the global market in 2017 and the trend is projected to continue during the forecast period. The segment is anticipated to expand at a high CAGR during the forecast period. This is attributed to rise in focus of market players to meet high demand in hospitals and to avoid stocking of drugs with the retailers. Moreover, these drugs are used in emergency procedures, hence are most commonly available in hospital pharmacies.

In terms of region, the global anticoagulant reversal drugs market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America and Europe, cumulatively, accounted for over 77% share of the global market in 2017. North America was the dominant market in 2017 and the trend is anticipated to continue during the forecast period. The market in the region is expected to grow at a high CAGR during the forecast period, owing to increase in product approvals, focus of major players on research and development, well-established health care infrastructure, and approval of AndeXXa. Europe is likely to be the next dominant market. Ongoing clinical trials on AndeXXa and anticipated launch in mid-2019 is anticipated to drive the market in the region. The market in Asia Pacific is projected to be driven by rise in patient pool owing to increase in geriatric population and focus on enhancing health care facilities.

Key companies operating in the global anticoagulant reversal drugs market include Bausch Health Companies, Inc., Pfizer, Inc., Fresenius Kabi AG, Amneal Pharmaceuticals, Inc., Boehringer Ingelheim GmbH, CSL Limited, Octapharma AG, Portola Pharmaceuticals, Inc., and Perosphere Pharmaceuticals, Inc.

Global Anticoagulant Reversal Drugs Market: Overview

The global anticoagulant reversal drugs market report comprises an elaborate executive summary, which includes a snapshot that provides information about various segments of the market. It also provides information and data analysis of the global market with respect to the segments based on product, distribution channel, and region. A detailed qualitative analysis of drivers and restraints of the market and opportunities has been provided in the overview section. Additionally, the section comprises competitive matrix and company profiles along with business overview to understand the competitive landscape in the market. This section of the report also provides market attractiveness analysis by region, thereby presenting a thorough analysis of the overall competitive scenario in the global anticoagulant reversal drugs market. 

Global Anticoagulant Reversal Drugs Market: Key Segments

In terms of product, the global anticoagulant reversal drugs market has been segmented into prothrombin complex concentrates, vitamin K, protamine, tranexamic acid, idarucizumab, AndeXXa, and others. Based on distribution channel, the global market has been classified into hospital pharmacies, retail pharmacies, and others. The hospital pharmacies segment is anticipated to expand at a high CAGR during the forecast period. The market has been analyzed based on price variations, technology trend, and presence of key players. The market size and forecast for each of these segments have been provided for the period from 2016 to 2026, along with their respective CAGRs for the forecast period from 2018 to 2026, considering 2017 as the base year. 

Global Anticoagulant Reversal Drugs Market: Regional Outlook

Geographically, the global anticoagulant reversal drugs market has been segmented into five major regions: North America (the U.S. and Canada), Europe (the U.K., Germany, France, Spain, Italy, and Rest of Europe), Asia Pacific (China, India, Japan, Australia, and Rest of Asia Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), and Middle East (South Africa, GCC Countries, Israel, and Rest of Middle East & Africa). The market size and forecast for each of these regions and the mentioned countries/sub-regions have been provided for the period from 2016 to 2026, along with their respective CAGRs for the forecast period from 2018 to 2026, considering 2017 as the base year. The research study also covers the competitive scenario in these regions. 

Companies Mentioned in Report

The report also profiles the major players in the market in terms of attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. Key companies profiled in the global anticoagulant reversal drugs market include Bausch Health Companies, Inc., Pfizer, Inc., Fresenius Kabi AG, Amneal Pharmaceuticals, Inc., Boehringer Ingelheim GmbH, CSL Limited, Octapharma AG, Portola Pharmaceuticals, Inc., and Perosphere Pharmaceuticals, Inc. 

The global anticoagulant reversal drugs market has been segmented as follows:

Global Anticoagulant Reversal Drugs Market, by Product

  • Prothrombin Complex Concentrates (PCC)
  • Vitamin K
  • Protamine
  • Tranexamic Acid
  • Idarucizumab
  • AndeXXa
  • Others

Global Anticoagulant Reversal Drugs Market, by Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Others

Global Anticoagulant Reversal Drugs Market, by Region

  • North America
    • U.S.
    • Canada 
  • Europe
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Rest of Europe 
  • Asia Pacific
    • China
    • Japan
    • Australia
    • India
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America 
  • Middle East & Africa
    • South Africa
    • GCC Countries
    • Israel
    • Rest of Middle East & Africa
.